



Press release | Lund 2024-11-21

Coegin Pharma's Nomination Committee appointed for the 2025 Annual General Meeting

The Nomination Committee of Coegin Pharma has been appointed in accordance with the guidelines for the Nomination Committee adopted at the Annual General Meeting on 23 May 2024.

The following individuals have been appointed as members of the Nomination Committee for the 2025 Annual General Meeting:

- Johan Arver (Chairman), representing Alveco Invest AB.
- Martin Tisell, representing own shareholdings.
- Rune Löderup, representing own shareholdings.
- Eva Sjökvist Saers, in her capacity as Chair of the Board of Directors of Coegin Pharma AB.

The Nomination Committee is tasked with performing the duties assigned to it according to the Swedish Corporate Governance Code. The Committee is responsible for preparing proposals for the 2025 Annual General Meeting regarding the Chair of the Meeting, the Board of Directors, the Chair of the Board, the auditor, board and auditor fees, as well as any potential changes to the guidelines for the Nomination Committee.

The Annual General Meeting will be held on 22 May 2025 in Lund, Sweden.

Shareholders who wish to submit proposals to the Nomination Committee are welcome to do so no later than 15 January 2025. Proposals should be sent via email to info@coeginpharma.com.

The Nomination Committee's proposals will be presented in the notice of the Annual General Meeting, as well as on the company's website www.coeginpharma.com.

For further information, please contact:


Jens Eriksson, CEO
Email: info@coeginpharma.com
Phone: +46 72 221 24 21

This document is a translation of the original Swedish press release. In case of any discrepancies, the Swedish version shall prevail.

About Coegin Pharma

Coegin Pharma is a Swedish biotech company with dermacosmetic innovations for hair growth and skin pigmentation, alongside groundbreaking drug candidates for the treatment of

Coegin Pharma AB
c/o Medicon Village
223 81 Lund, Sweden
Registration number
559078-0465
coeginpharma.com
info@coeginpharma.com





myocardial infarction, leukemia and skin cancer. Coegin Pharma is planning for the launch of its first product series for hair growth in 2025, followed by a skin pigmentation product in 2026.

Coegin Pharma's share is listed on NGM Nordic SME and is dual-listed on Börse Stuttgart. The company has a registered office in Lund, Sweden.

For more information, please visit: coeginpharma.com/en

Coegin Pharma AB
c/o Medicon Village
223 81 Lund, Sweden
Registration number
559078-0465
coeginpharma.com
info@coeginpharma.com